High Purity Pharmaceutical Grade Raw Material Ruxolitinib CAS 941678-49-5 Ruxolitinib
Product Description
Product Details
| Product Name |
Ruxolitinib |
| Appearance |
White to off-white crystalline powder |
| Assay |
99% |
| MF |
C17H18N6 |
| MW |
306.37 |
Ruxolitinib is a selective kinase inhibitor that inhibits Janus-associated kinases (JAKs) JAK1 and JAK2. It functions by blocking the JAK signal transduction and transcriptional activator factor (STAT) pathways. The JAK-STAT signaling pathway plays a crucial role in the signal transduction of many cytokines and growth factors related to cell proliferation, growth, and hematopoiesis. MF is associated with the upregulation of JAK1/JAK2-specific gene expression, leading to overall persistent disorder of the JAK-STAT signaling pathway. Although more than half of MF patients have JAK2V617F gene mutations, studies have shown that abnormal JAK-STAT regulation is the main cause of MF onset, regardless of whether there is a JAK2V617F mutation. Therefore, JAK1 and JAK2 have become the targets for the development of MF treatment drugs.
Application&Function
This drug is an inhibitor of Janus-related kinases (JAK family) JAK1 and JAK2. It can be used for adult patients with intermediate-risk or high-risk primary myelofibrosis (PMF), also known as chronic idiopathic myelofibrosis, secondary myelofibrosis due to polycythemia vera (PPV-MF), or secondary myelofibrosis due to essential thrombocythemia (PET-MF), for treating disease-related splenomegaly or disease-related symptoms.
Packaging & Shipping
ABOUT US
){kind=link}